Acute and chronic human leukemias are frequently associated with chromosomal translocations which result in the formation of chimeric proteins. Considerable evidence indicates that these chimeric proteins play a role in transformation (1) . At least one member of the chimeric protein is frequently a transcription factor, implicating disordered regulation of target genes as a mechanism of transformation. In most cases the role of these transcription factors in normal hematopoiesis has not been determined.
Recently a member of the ets family of transcription factors, Tel, was identified at the site of chromosomal breakage in chronic myelomonocytic leukemia (CMML) where it forms a chimeric protein with the transmembrane and tyrosine kinase domains of the platelet-derived growth factor receptor ␤ chain (PDGFR␤) (2) . Tel has now been shown to be involved in a number chromosomal translocations in human leukemias. The Tel-AML-1 fusion is present in approximately 40% of cases of childhood pre-B cell acute lymphoblastic leukemia (ALL), 1 making it the most common molecular abnormality in childhood cancer (3) (4) (5) . In a number of cases involving tel translocations, the remaining tel allele is deleted, suggesting that loss of functional Tel may contribute to leukemic transformation.
Tel contains the highly conserved ETS DNA-binding domain at the carboxyl-terminal region as well as a distinct 5Ј region with weak homology to the well described helix-loop-helix (HLH) domain (also referred to as the pointed domain) (2) . The predicted HLH secondary structure in the amino-terminal region suggests that this region may be involved in proteinprotein interactions (6) .
To identify potential protein partners of Tel, we screened a hematopoietic stem cell library using Tel in the bait plasmid (7) . We identified two partners of Tel, Tel itself, and the ets protein Fli-1.
EXPERIMENTAL PROCEDURES
Two-hybrid Library Screening-Two-hybrid screens and parent vectors pBTM116 and pVP16 were as described by (8) . Plasmid pLexA-Tel-(1-371) was constructed by insertion of the Tel polymerase chain reaction (PCR) product encoding amino acids from 1 to 371 into EcoRIBamHI sites of pBTM116, resulting in an open reading frame encoding a LexA-Tel fusion protein. Tel was constructed by PCR with the following primers: 5Ј-CGGAATTCCGGATGTCTGAGACTCCTGCTCA-GT-3Ј (coding strand) and 5Ј-CGGGATCCCGTGAGGTGGACTGTTGG-TTCCTTC-3Ј (noncoding strand). The PCR product was cut with EcoRI and BamHI, and the 1125-bp fragment was cloned. The EML-1 cell line cDNA library was amplified once in DH5␣ and transformed into yeast containing pLexA-Tel-(1-371) (7) . Plasmids pVP-Tel-(19 -163), pVP-Fli-(32-334), and pVP-Fli-(14 -230) were identified as clones that activated lacZ transcription and conferred histidine prototrophy in the presence of pLexA-Tel-(1-371). Binding specificity was confirmed in the mating test with specific bait pLexA-Tel-(1-371) versus nonspecific bait pLexALamin (pBTM116 expressing LexA-Lamin fusion protein). Plasmids were sequenced by automatic fluorescent sequencing (Applied Biosystems).
In Vitro Transcription Translation and Protein Binding Assay-In vitro transcription-translation was performed in TNT rabbit reticulocyte lysate (Promega, Madison, WI) in the presence of L-[
35 S]methionine (specific activity 37.0 TBq/mmol) (Amersham Pharmacia Biotech). All clones were transcribed under the control of T7 promoter. In each case, 2 l of a 25-l translation reaction was analyzed by SDS-PAGE (see Fig.  2A .). Radiolabeled Fli-1 protein (5 l of translation reaction) was mixed with one of each radiolabeled proteins, PU.1, CD18, CD11a, RAR␣, Luciferase, or Tel-(1-371) (5 l of translation reaction in each case) and immunoprecipitated with mouse monoclonal anti human Fli-1 antibody (PharMingen, San Diego, CA) and assayed by SDS-PAGE followed by autoradiography.
GST Fusion Protein Binding Assay-Plasmids pGST-Fli and pGSTTel-(1-371) were cloned by linking the full-length coding sequence of Fli-1 protein (amino acids 1-452) and the coding sequence for amino * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. (10) . Forty eight h after transfection, the cells were washed with PBS and lysed by incubation for 10 min at 4°C in cell lysis buffer (150 mM NaCl, 20 mM Tris (pH 8.0), 5 mM EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM aprotinin, 1 mM leupeptin). 20 -100 l of 293 cell extracts were immunoprecipitated with mouse monoclonal anti-Myc antibody (␣myc 9E10, Sigma) or nonspecific mouse IgG (Sigma). Immunoprecipitated proteins were resolved by electrophoresis in 7.5% SDS gels. Protein immunoblots were probed with Tel antiserum produced by five sequential immunizations of a rabbit with synthesized peptide H-TNHRPSPDPEQR-PLRC-OH (Research Genetics, Huntsville, AL) emulsified with Freund's Adjuvant. This antiserum detected all forms of human Tel protein used in this study on Western blots and showed no crossreactivity with any other human protein.
In Vivo Tel-Fli-1 Protein Binding Assay-Human K562 erythroleukemia cells were cultured in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum. For electroporations, 300 l of ϳ8 ϫ 10 6 cells/ml, washed and resuspended in RPMI 1640, was mixed with 10 g of pL(Fli-1)SN plasmid (wild type human Fli-1 coding sequence ligated into HpaI/XhoI site of pLXSN vector) and 10 g of pSG5-Tel-(1-452) in a 2-mm gap electroporation cuvette (BTX, San Diego, CA). Cells were electroporated with 275 V, 600 microfarads, and 13 ohm using Elecro Cell Manipulator 600 (BTX). After 48 h of incubation in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum, cells were harvested and lysates were prepared as described previously. 100 -200 l of lysate was immunoprecipitated with mouse monoclonal anti-human Fli-1 antibody (PharMingen). Rabbit polyclonal antiserum directed against the human Tel protein was used for detection.
Western Blot Detection of Tel and Fli-1 in CD34ϩ
Cells-CD34ϩ cells were purified and cultured as described (11) . For differentiation, growth factors interleukin-3 (IL-3), IL-6, G-CSF, and GM-CSF and stem cell factor (SCF) were added to a final concentration of 50 ng/ml. Lysates were created from identical numbers of cells at designated time periods. Anti-Tel and anti-Fli-1 antibodies were used to detect their respective proteins.
Transactivation Luciferase Assays-For transactivation assays, 293 cells were transiently transfected by the calcium-phosphate method with 5 g of each of the indicated plasmids, and cell lysates were prepared after 48 h of incubation. For internal control of transfection efficiency, all samples were co-transfected with the vector pCMV-GH (Nichols Institute, San Juan Capistrano, CA) expressing human growth hormone. Twenty l of cell lysate was assayed for luciferase activity by using Promega luciferase assay kit according to the instructions of the manufacturer. The activity was assayed by using a Turner two-dimensional 20e luminometer. The growth hormone assay was performed by the use of HGH-TGES 100T kit (Nichols Institute) according to the instructions of the manufacturer.
RESULTS AND DISCUSSION
To identify potential partners of Tel in normal hematopoietic cell development, we used a LexA-Tel fusion protein consisting of the first 371 amino acids of Tel to screen a yeast two-hybrid library constructed from a murine pluripotent hematopoietic cell line (EML-1) (7). The fragment of Tel used in the bait plasmid contains the HLH domain. Five positive clones were identified from 2 ϫ 10 6 transformants screened. Two ets family members were identified as partners of Tel, Tel itself and Fli-1 (Fig. 1) . The two 435-bp Tel cDNA clones that were isolated include the entire HLH domain, and the three positive clones coding for Fli-1 also include the HLH domain ( Fig. 1) (12) . These results suggest that the amino-terminal HLH domain in each protein is involved in the interaction.
To confirm the specificity of the Tel/Tel and Tel/Fli-1 interaction, we conducted both in vitro and in vivo experiments. Initially, we expressed several proteins known to be involved in protein-protein interactions using rabbit reticulocyte lysates ( Fig. 2A) . These proteins were then used in a co-immunoprecipitation assay (Fig. 2B) . Monoclonal antibodies directed against Fli-1 immunoprecipitated the human Tel protein (amino acids 1-371) but none of the control proteins (Fig. 2B, (Fig. 2D) . Neither mouse nonspe- cific IgG (Fig. 2D) (Fig. 2E) . The Tel protein was not present in lysates immunoprecipitated with nonspecific mouse IgG and probed with the anti-Tel antibody (Fig. 2E) .
To identify the stage of hematopoietic cell development at which Tel and Fli-1 are expressed, human CD34ϩ cells were differentiated with IL-3, IL-6, SCF, G-CSF, and GM-CSF, and the appearance of Tel and Fli-1 proteins was detected by Western blotting. Fli-1 protein was expressed at day 0, peaked at day 2 of differentiation, and decreased to undetectable levels by day 4 (Fig. 3A) . Interestingly, the Tel protein displayed a similar pattern of appearance with a peak at 2 days of differentiation and a decrease to undetectable levels by day 4 (Fig. 3B) .
To determine whether Tel and Fli-1 displayed a functional interaction, the transactivation abilities of Tel and Fli-1 proteins were tested individually and in concert on promoters containing ETS binding sites (Fig. 4A) . Recombinant Fli-1 has been shown to bind to DNA in a sequence-specific manner and to transcriptionally activate the platelet glycoprotein IIb promoter (12, 13) . In this study, we used the promoters from the related megakaryocytic genes GPIb␣ (14) and GPIX (15) which contain ETS sequences. The GPIb␣ promoter region extended to Ϫ567 bp upstream from the transcriptional start site, and the GPIX promoter region covered 203 bp proximal to the transcriptional start site. Transfection of Fli-1 resulted in a 3.5-fold increase of activity of the GPIb␣ promoter and a 7-fold increase in the activity of the GPIX promoter (Fig. 4, B and C) . Expression of Tel alone did not activate either promoter; however, co-transfection of Tel with Fli-1 together resulted in complete inhibition of Fli-1-mediated transactivation (Fig. 4, B and  C) . Transfection of Fli-1, Tel, or the two ets factors together did not transactivate a GPIX promoter construct in which the ETS site was deleted (pGPIX-EETS-Luc) (Fig. 4D) . Thus, Tel inhibits Fli-1-mediated transactivation of megakaryocytic promoters
FIG. 4. Transactivation of GPIb␣ and GPIX promoters by Fli-1 and Tel proteins in transient transfection experiments.
A, schematic representation of the GPIb␣ and GPIX promoter constructs. GPIb␣ promoter spans the proximal 567 bp, with identified ETS and GATA binding sites at positions Ϫ150 and Ϫ93, respectively. GPIX wild type promoter consisted of Ϫ203 bp proximal to transcriptional start site and includes GATA and ETS binding sites at positions Ϫ67 and Ϫ45, respectively. GPIX(EETS) promoter contains a mutated ETS binding site generated by PCR mutagenesis. B, 293T cells were cotransfected by the calcium phosphate technique. The graph shows luciferase activity (relative light units ϩ S.D.) generated by the constructs divided by the amount of growth hormone constitutively expressed by the pCMV-GH plasmid to normalize for variations in transfection efficiency. The transactivation magnitudes were confirmed in at least three separate experiments with each sample in triplicate. C, the proximal Ϫ203-bp GPIX promoter was used in transactivation assay performed as in panel C. D, the effect of disruption of the ETS binding site in Ϫ203-bp GPIX promoter on Fli-1 and Tel transactivation abilities.
as GPIb␣ and GPIX (Fig. 4) and as GPIIb (data not shown), and the ETS binding site in the promoter sequence is required for transactivation.
To analyze the mechanism whereby Tel inhibits Fli-1-mediated transactivation in more detail, we generated deletion mutants of Tel. The Tel H protein consists of the HLH domain of Tel, and Tel D consists of the DNA binding domain of Tel (Fig.  5A) . To assess whether Tel fusion proteins identified in human leukemias are capable of inhibiting the transactivation mediated by Fli-1, we also expressed the Tel-AML-1 fusion protein present in childhood acute lymphoblastic leukemia. These constructs were tested in transactivation assays with Fli-1 on the GPIX promoter. Transfection of the Tel and Fli-1 constructs were adjusted to achieve expression of equivalent amounts of respective proteins (Fig. 5C ). In these experiments, wild type Tel was able to completely abrogate transactivation (Fig. 5B) . The Tel H, Tel D, and Tel-AML-1 constructs partially inhibited Fli-1-mediated transactivation (Fig. 5B) . Similar data have been obtained using the GPIb␣ promoter (data not shown). These data indicate that full-length Tel protein is necessary to completely repress Fli-1-mediated transactivation. The Tel H construct, lacking the DNA binding domain, inhibits Fli-1-mediated transactivation by approximately 50%, indicating that protein-protein interaction between Tel and Fli-1 most likely accounts for this effect. The mechanism whereby the Tel D construct inhibits transactivation has not been established. We and others have not been able to demonstrate DNA-binding activity by Tel (data not shown). It is possible that the Tel DNA-binding domain may recruit a generalized transcriptional repressor to the promoter.
To determine whether overexpression of the Tel truncation constructs abrogated Fli-1-mediated transactivation of the GPIX promoter, titration experiments were performed. Transactivation experiments were conducted using increasing molar ratios of Tel expression constructs (Tel, Tel H, Tel D, and Tel-AML-1) to Fli-1 expressing plasmid DNA (Fig. 6 ). Three sets of transactivations were performed with Tel constructs to Fli-1 DNA molar ratios of 1:1, 2.5:1, and 5:1, respectively. Increasing amounts of Tel H or Tel D protein resulted in only a small effect on the ability of these proteins to inhibit Fli-1 transactivation of the GPIX promoter (Fig. 6 ). The addition of increasing amounts of Tel-AML-1 resulted in a modest increase in the ability of the fusion protein to repress Fli-1-mediated transactivation. These results confirm our previous observation that the full-length Tel protein is necessary to completely inhibit Fli-1 transactivation of the GPIX promoter, and they indicate that the effect of the Tel mutant proteins appears to reach a plateau at a 1:1 molar ratio.
With Tel-AML-1, the expression of the chimeric protein in these studies may not represent the physiological level of the protein in cells from ALL patients because, in at least one ALL cell line expressing Tel-AML-1 protein (the REH cell line), the level of expression of Fli-1 was more than 10-fold higher then the expression of Tel-AML-1 (data not shown). The wild type Tel protein is not expressed by REH cells. In this cell line, it is possible that the low molar ratio of Tel-AML-1 protein to Fli-1 protein expression may not be sufficient to inhibit the activation of Fli-1 target genes in these ALL cells.
Ets family members have been identified at the site of chromosomal translocations in primitive stem cell tumors including leukemia (16) . The identification of Fli-1 as a partner of Tel is of interest for several reasons. First, the interaction of Tel with Fli-1 was unexpected since ets family members have previously not been demonstrated to form heterodimers with others ets family members (17) . Second, Fli-1 is involved in malignancies in both mouse and man. Mouse fli-1 (Friend leukemia integration site 1) gene was identified originally as a proto-oncogene insertionally activated in 75% of erythroleukemias derived from newborn mice infected with F-MuLV (Friend murine leukemia virus (18)). Erythroleukemia cell lines induced by FMuLV expressed high levels of Fli-1 transcript (18) . The human homologue of fli-1 is rearranged in Ewing's sarcoma and neuroepithelioma as a result of a reciprocal chromosomal translocation t(11;22) that fuses the DNA binding domain of Fli-1 to a novel amino-terminal sequence of the Ews gene (19) . Thus, not only is Fli-1 involved in human and mouse malignancies, but its DNA-binding domain is preserved in both instances.
There are reasons to suspect that Tel and Fli-1 may have opposing roles in development. Whereas Fli-1 translocations preserve the DNA binding domain of Fli-1, the translocations involving Tel almost invariably result in the loss of the Tel DNA binding domain and preserve the helix-loop-helix domain of Tel in the fusion protein. This suggests that Fli-1 retains its ability to recognize its target genes as a fusion protein and Tel does not.
In Tel translocations, the chimeric Tel fusion protein may also dimerize with the normal Tel protein from the other allele and result in a loss of normal, wild-type Tel function (3) (4) (5) . The observation that the remaining Tel allele is deleted in up to one-third of patients with the Tel/AML-1 translocation is consistent with the loss-of-function hypothesis of Tel as a result of the generation of the chimeric protein (3) (4) (5) . Loss of Tel would also result in the loss of its ability to dimerize with Fli-1. Future studies will address the effect of Tel and Fli-1, and their respective fusion proteins, on the process of malignant transformation.
